Why the study?
Do GPIIb/IIIa antagonists like c7E3 Fab reduce ischemic complications in high-risk patients undergoing percutaneous coronary interventions?
Do GPIIb/IIIa antagonists like c7E3 Fab reduce ischemic complications in high-risk patients undergoing percutaneous coronary interventions?
This review summarizes the pharmacology, mechanisms, and clinical utility of GPIIb/IIIa antagonists like abciximab in reducing ischemic complications during high-risk percutaneous coronary interventions.
Answers are grounded in this paper and cite their sources.
No data on GPIIb/IIIa antagonists in PCI; leaves open the need for randomized trials before clinical adoption.
Platelet GPIIb/IIIa receptor antagonists have been shown to be more potent than aspirin in inhibiting platelet function in vitro and decreasing thrombotic vascular events in animal models in vivo. One of these agents (c7E3 Fab, abciximab, ReoPro) significantly decreased the ischemic complications of percutaneous coronary interventions when given in conjunction with aspirin and heparin to patients at high risk of such complications, and other agents (Integrelin and tirofiban) have shown favorable trends. This review focuses on what we have learned from studies of patients treated with c7E3 Fab, including its pharmacology, its potential mechanism(s) of action, the ability to reverse its effects with platelet transfusion, and the risks of hemorrhage, thrombocytopenia, reinjection, and performing coronary artery bypass surgery. The future of GPIIb/IIIa antagonists therapy is considered, including the potential of orally active agents.
No takes yet. Share an insight, caveat, or question.
Barry S. Coller (1997) reported a review. c7E3 Fab was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: